ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements with these filters
Promoter group trust Hardik Desai Family Trust bought 5,412 Trident Texofab shares on BSE. Promoter stake rose from 6.95% to 6.99%.
Hardik Desai Family Trust, a Promoter Group entity, bought 5,412 shares of Trident Texofab in the open market. Post-transaction holding rose to 6.99% of total equity.
Trident Texofab Limited has issued the notice for its 18th Annual General Meeting, scheduled for September 30, 2026, alongside its Annual Report for FY 2025-26.
Trident Texofab Limited has appointed M/s. PAAA & Associates as the Cost Auditor for the company, effective September 7, 2026.
Trident Texofab's board approved the Board's Report, called the 18th AGM for September 30, 2026, and appointed a cost auditor and scrutinizer.
CRISIL Ratings has withdrawn the credit rating for Trident Texofab Ltd. This action follows a recent review of the company's financial and operational standing.
Trident Texofab Limited has voluntarily withdrawn its credit ratings from CRISIL for bank facilities totaling Rs. 20 Crore. The ratings were reaffirmed at CRISIL B/Stable before withdrawal.
Hardik Desai Family Trust, a promoter group entity, acquired 15,000 shares of Trident Texofab Limited. This open-market transaction increased the promoter's stake to 6.89%.
Hardik Desai Family Trust, part of the promoter group, acquired 39,158 shares of Trident Texofab Ltd via open market, increasing their stake by 0.26%.
Trident Texofab Limited has announced the resignation of Shah Kailash & Associates LLP as Statutory Auditor and the appointment of Prit Agrawal & Co as Internal Auditor.
Trident Texofab Limited announced the resignation of its statutory auditor, Shah Kailash & Associates LLP, effective August 10, 2026, due to increasing professional workload.
Trident Texofab Ltd reported revenue from operations of ₹26.1 Cr (-7.1% YoY) and net profit of ₹0.5 Cr (-50.0% YoY) for Q1 FY27.
Trident Texofab will hold a board meeting on August 10, 2026. The meeting will consider the company's standalone financial results for the quarter ended June 30, 2026.
Trident Texofab forfeited 9,11,479 unexercised warrants after the exercise deadline passed. Outstanding convertible warrants are now nil.